288 related articles for article (PubMed ID: 29107960)
1. Glutamine deficiency induces DNA alkylation damage and sensitizes cancer cells to alkylating agents through inhibition of ALKBH enzymes.
Tran TQ; Ishak Gabra MB; Lowman XH; Yang Y; Reid MA; Pan M; O'Connor TR; Kong M
PLoS Biol; 2017 Nov; 15(11):e2002810. PubMed ID: 29107960
[TBL] [Abstract][Full Text] [Related]
2. A ubiquitin-dependent signalling axis specific for ALKBH-mediated DNA dealkylation repair.
Brickner JR; Soll JM; Lombardi PM; Vågbø CB; Mudge MC; Oyeniran C; Rabe R; Jackson J; Sullender ME; Blazosky E; Byrum AK; Zhao Y; Corbett MA; Gécz J; Field M; Vindigni A; Slupphaug G; Wolberger C; Mosammaparast N
Nature; 2017 Nov; 551(7680):389-393. PubMed ID: 29144457
[TBL] [Abstract][Full Text] [Related]
3. Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer.
Grinde MT; Hilmarsdottir B; Tunset HM; Henriksen IM; Kim J; Haugen MH; Rye MB; Mælandsmo GM; Moestue SA
Breast Cancer Res; 2019 May; 21(1):61. PubMed ID: 31088535
[TBL] [Abstract][Full Text] [Related]
4. Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents.
Wang P; Wu J; Ma S; Zhang L; Yao J; Hoadley KA; Wilkerson MD; Perou CM; Guan KL; Ye D; Xiong Y
Cell Rep; 2015 Dec; 13(11):2353-2361. PubMed ID: 26686626
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism.
Huang Q; Stalnecker C; Zhang C; McDermott LA; Iyer P; O'Neill J; Reimer S; Cerione RA; Katt WP
J Biol Chem; 2018 Mar; 293(10):3535-3545. PubMed ID: 29317493
[TBL] [Abstract][Full Text] [Related]
6. Rhein Inhibits AlkB Repair Enzymes and Sensitizes Cells to Methylated DNA Damage.
Li Q; Huang Y; Liu X; Gan J; Chen H; Yang CG
J Biol Chem; 2016 May; 291(21):11083-93. PubMed ID: 27015802
[TBL] [Abstract][Full Text] [Related]
7. Vemurafenib resistance reprograms melanoma cells towards glutamine dependence.
Hernandez-Davies JE; Tran TQ; Reid MA; Rosales KR; Lowman XH; Pan M; Moriceau G; Yang Y; Wu J; Lo RS; Kong M
J Transl Med; 2015 Jul; 13():210. PubMed ID: 26139106
[TBL] [Abstract][Full Text] [Related]
8. DNA unwinding by ASCC3 helicase is coupled to ALKBH3-dependent DNA alkylation repair and cancer cell proliferation.
Dango S; Mosammaparast N; Sowa ME; Xiong LJ; Wu F; Park K; Rubin M; Gygi S; Harper JW; Shi Y
Mol Cell; 2011 Nov; 44(3):373-84. PubMed ID: 22055184
[TBL] [Abstract][Full Text] [Related]
9. Novel 1,3,4-Selenadiazole-Containing Kidney-Type Glutaminase Inhibitors Showed Improved Cellular Uptake and Antitumor Activity.
Chen Z; Li D; Xu N; Fang J; Yu Y; Hou W; Ruan H; Zhu P; Ma R; Lu S; Cao D; Wu R; Ni M; Zhang W; Su W; Ruan BH
J Med Chem; 2019 Jan; 62(2):589-603. PubMed ID: 30543285
[TBL] [Abstract][Full Text] [Related]
10. Targeting Glutamine Induces Apoptosis: A Cancer Therapy Approach.
Chen L; Cui H
Int J Mol Sci; 2015 Sep; 16(9):22830-55. PubMed ID: 26402672
[TBL] [Abstract][Full Text] [Related]
11. Acidosis-induced metabolic reprogramming in tumor cells enhances the anti-proliferative activity of the PDK inhibitor dichloroacetate.
Schoonjans CA; Joudiou N; Brusa D; Corbet C; Feron O; Gallez B
Cancer Lett; 2020 Feb; 470():18-28. PubMed ID: 31812695
[TBL] [Abstract][Full Text] [Related]
12. Transient kinetic analysis of oxidative dealkylation by the direct reversal DNA repair enzyme AlkB.
Baldwin MR; Admiraal SJ; O'Brien PJ
J Biol Chem; 2020 May; 295(21):7317-7326. PubMed ID: 32284330
[TBL] [Abstract][Full Text] [Related]
13. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
[TBL] [Abstract][Full Text] [Related]
14. DNA alkylation lesion repair: outcomes and implications in cancer chemotherapy.
Peng Y; Pei H
J Zhejiang Univ Sci B; 2021 Jan; 22(1):47-62. PubMed ID: 33448187
[TBL] [Abstract][Full Text] [Related]
15. Novel Metabolically Stable PCA-1/ALKBH3 Inhibitor Has Potent Antiproliferative Effects on DU145 Cells
Ueda M; Shimizu T; Mabuchi M; Horiike K; Kitae K; Hase H; Ueda Y; Tsujikawa K; Tanaka A
Anticancer Res; 2018 Jan; 38(1):211-218. PubMed ID: 29277775
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic targeting of glutaminolysis as an essential strategy to combat cancer.
Matés JM; Di Paola FJ; Campos-Sandoval JA; Mazurek S; Márquez J
Semin Cell Dev Biol; 2020 Feb; 98():34-43. PubMed ID: 31100352
[TBL] [Abstract][Full Text] [Related]
17. Enhancing the Efficacy of Glutamine Metabolism Inhibitors in Cancer Therapy.
Yang WH; Qiu Y; Stamatatos O; Janowitz T; Lukey MJ
Trends Cancer; 2021 Aug; 7(8):790-804. PubMed ID: 34020912
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer.
Gross MI; Demo SD; Dennison JB; Chen L; Chernov-Rogan T; Goyal B; Janes JR; Laidig GJ; Lewis ER; Li J; Mackinnon AL; Parlati F; Rodriguez ML; Shwonek PJ; Sjogren EB; Stanton TF; Wang T; Yang J; Zhao F; Bennett MK
Mol Cancer Ther; 2014 Apr; 13(4):890-901. PubMed ID: 24523301
[TBL] [Abstract][Full Text] [Related]
19. Glutaminase Inhibitors Induce Thiol-Mediated Oxidative Stress and Radiosensitization in Treatment-Resistant Cervical Cancers.
Rashmi R; Jayachandran K; Zhang J; Menon V; Muhammad N; Zahner M; Ruiz F; Zhang S; Cho K; Wang Y; Huang X; Huang Y; McCormick ML; Rogers BE; Spitz DR; Patti GJ; Schwarz JK
Mol Cancer Ther; 2020 Dec; 19(12):2465-2475. PubMed ID: 33087507
[TBL] [Abstract][Full Text] [Related]
20. Regulation of DNA Alkylation Damage Repair: Lessons and Therapeutic Opportunities.
Soll JM; Sobol RW; Mosammaparast N
Trends Biochem Sci; 2017 Mar; 42(3):206-218. PubMed ID: 27816326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
